Table 2.
Subgroup analysis of circulating chemerin levels in MAFLD patients compared with controls
| All studies | ||||
|---|---|---|---|---|
| Studies | SMD (95% CI) | I2(%) | P for heterogeneity | |
| Overall | 15 | 1.32 (0.29, 2.35) | 98.9 | < 0.0001 |
| Subgroup analysis | ||||
| Region | ||||
| Asian | 10 | 1.73 (0.35, 3.10) | 99.3 | < 0.0001 |
| Others | 5 | 0.50 (-0.61, 1.60) | 93.9 | < 0.0001 |
| Mean age (y) | ||||
| <50 | 12 | 1.91 (1.44, 2.39) | 91.3 | < 0.0001 |
| ≥ 50 | 3 | -1.10 (-1.93, -0.27) | 92 | < 0.0001 |
| Study design | ||||
| Case-control | 8 | 2.04 (1.37, 2.70) | 95.5 | < 0.0001 |
| Cross-sectional | 7 | 0.48 (-1.01, 1.97) | 99 | < 0.0001 |
CI confidence interval, MAFLD metabolic-associated fatty liver disease, SMD standardized mean difference